As part of our ongoing series focussing on new registrations in Australia, we have uploaded a product review of the use of small-molecule JAK inhibitor baricitinib in patients with moderate-to-severe rheumatoid arthritis. This review discusses evidence in support of the use of baricitinib, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Kevin Pile, Director of Medicine and Senior Staff Rheumatologist at Campbelltown Hospital, Sydney and Conjoint Professor at Western Sydney University.
Please login below to download this issue (PDF)